Guru Sonpavde/adventhealth.com
May 25, 2025, 16:16
Guru Sonpavde: Role of Adjuvant Therapy in Current Perioperative Immunotherapy-Based Trials in Bladder Cancer
Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, shared a post on Linkedin:
“Bladder Cancer perioperative therapy commentary in European Urology Focus – Perioperative durvalumab (ie not just neoadjuvant) combined with neoadjuvant cisplatin-based chemotherapy should be the current preferred strategy for most patients with muscle-invasive disease based on results of the NIAGARA trial AstraZeneca
Until high-level evidence for validated biomarkers (e.g. ctDNA MRD assessment) in this setting becomes available from prospective trials, precision medicine in the perioperative setting is not ready for prime time -look for data from NIAGARA for ctDNA at ASCO25- pleased to comment from Advent Health Central Florida Cancer Institute”
Title: Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard
Author: Guru P. Sonpavde
You can read the Full Article on European Urology Focus.
More posts featuring Guru Sonpavde.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 25, 2025, 16:13
May 25, 2025, 15:53
May 25, 2025, 15:34
May 25, 2025, 15:28
May 25, 2025, 15:22
May 25, 2025, 15:09
May 25, 2025, 14:54